科技部南部科學園區管理局亮點投資案

泉沂醫學加入新冠病毒檢測行列，與南部智慧生醫產業聚落一同打擊疫情

日期 : 109年4月13日

發稿單位：南科管理局

聯絡人：侯志龍

電話：(06)505-1001#2171

E-mail：andyhou@stsp.gov.tw

新冠肺炎（武漢肺炎）疫情蔓延全球，全民防疫刻不容緩，近期全球媒體讚譽台灣的防疫有成，不論是超前佈署、衛生水平還是醫療能量儲備，已是各國醫衛及防疫的模範生。位於南部科學園區的泉沂醫學科技股份有限公司(以下簡稱泉沂醫學)於3月宣布，完成新冠病毒快速核酸檢測試劑的開發，與高雄醫學大學一同投入防疫檢測試驗。

泉沂醫學於2019年在南科設立，生產之核酸萃取/檢測試劑主要銷售於日本及台灣等檢驗科技公司和醫院實驗室，在新冠病毒爆發初期，基於醫檢單位即時反應其檢測需求，泉沂醫學立即投入資源，開發新冠病毒快速核酸分子檢測試劑，遵循WHO建議診斷方式，以60分鐘的螢光反應時間即可完成檢測結果。由於新冠病毒快速檢測試劑需進行臨床前效能驗證，泉沂醫學便與高雄醫學大學附設中和紀念醫院合作，在高醫鐘育志校長與余明隆副校長的協助下，於高醫熱帶醫學暨傳染病研究中心陳彥旭主任實驗室進行試劑驗證，並免費授與高醫1000個檢測反應。現已依美國(EUA)緊急程序送美國FDA認證，同時也檢送歐盟(CE)認證，期盼用高品質的產品為防疫盡一份心力。

泉沂醫學投資額為3,600萬元，團隊現有13人，屬於生技新創公司，未來新產品陸續完成開發後，預期營業額將持續成長。泉沂醫學結合南部智慧生醫產業聚落連結各醫衛資源與產業鏈，目前持續與各醫療機構與學術研究單位保持合作，藉著結合臨床醫學資源，簡化現有之臨床人類檢體之核酸萃取擴增檢測技術，才能在新冠肺炎疫情爆發之初便能即時應變，在現階段控制疫情蔓延的關鍵時刻為國人備戰。隨著國際防疫的重視，台灣醫衛水平與生物技術在國際曝光，泉沂醫學與南部智慧生醫產業聚落已備妥技術與能量，打擊疫情。

Press Release

April 13, 2020

GeneOne Diagnostics Corporation joins the campaign of detecting COVID-19, fighting the epidemic together with the STSP Intelligent Biotech Medical Cluster

    As the coronavirus disease (COVID-19) becomes a global pandemic, every citizen’s immediate effort is required to fight against it. Recently, media across the globe widely praised Taiwan’s achievement in epidemic prevention ranging from preemptive actions, high public health standards, and medical treatment preparedness; and Taiwan may serve as the role model for public health and epidemic prevention. GeneOne Diagnostics Corporation (GeneOne Crop.), located at the Southern Taiwan Science Park (STSP), announced a fast nucleic acid diagnostic kit for COVID-19 in March, and will collaborate with Kaohsiung Medical University (KMU) on clinical trials.

    GeneOne Crop. was founded at the STSP in 2019 and its nucleic acid extraction /diagnostic kits products mainly targeted towards diagnostic technology companies, hospitals, and laboratories in Japan and Taiwan. At the early stages of the COVID-19 epidemic, GeneOne Corp. dedicated in developing fast nucleic acid diagnostic kits for COVID-19, upon receiving feedbacks from medical laboratories reflecting their needs for the diagnosis. Following the diagnostic procedures recommended by WHO, the test result only takes 60 minutes of fluorescence reaction. In order to verify the preclinical efficiency, GeneOne Corp. is collaborating with Kaohsiung Medical University Chung-Ho Memorial Hospital. With KMU President Yuh-Jyh Jong and Vice President Ming-Lung Yu‘s assistance, trials of the diagnostic kit will be conducted in Dr. Yen-Hsu Chen’s lab in the Center for Tropical Medicine and Infectious Disease Research, with 1000 free reactions authorized. Hoping to help fighting the pandemic with the high quality product, GeneOne Corp. also submitted the diagnostic kit for certification to U.S. FDA according to the Emergency Use Authorization (EUA) and to the E.U. counterparts (CE).

    GeneOne Crop. has capital of 1.2 million USD with a 13-member team. As a biotech startup, its expected revenue will continue to grow when new products are launched. GeneOne Crop. as part of the STSP Intelligent Biotech Medical Cluster combines the health/medical resources with the industry chain. In particular, collaboration with hospitals and research institutes provides clinical resources that enable simplification of current diagnostic technologies based on nucleic acid extraction and amplification for clinical human samples. This was why GeneOne Corp. can react in time to be prepared for this critical moment of epidemic prevention and control. As epidemic prevention becomes a global effort and Taiwan’s medical standards and biotechnology receives international coverage, GeneOne Corp. and the STSP Intelligent Biotech Medical Cluster have the technology and readiness to fight the epidemic.

Media Contact

Andy Hou,

Investment Services Division, Southern Taiwan Science Park Bureau ,MOST

Tel：06-5051001 ext.2171   

E-mail：andyhou@stsp.gov.tw